目的 觀察核黃素磷酸鈉聯(lián)合干擾素治療小兒皰疹性咽峽炎的療效。方法 選取2012年10月—2015年4月重慶市沙坪壩區(qū)婦幼保健計(jì)劃生育服務(wù)中心收治的皰疹性咽峽炎患兒100例,隨機(jī)分為對(duì)照組和治療組,每組各50例。兩組患者均給予物理或藥物降溫、補(bǔ)液支持、抗菌素治療等常規(guī)治療。對(duì)照組在此基礎(chǔ)上霧化吸入重組人干擾素α1b注射液,6個(gè)月~1歲6 μg/次,1~3歲10 μg/次,3歲以上20 μg/次,1次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注稀釋后的核黃素磷酸鈉5~10 mg,1次/d。觀察兩組患者的臨床療效,并比較兩組患者皰疹潰瘍消失時(shí)間、流涎消失時(shí)間、退熱時(shí)間、住院時(shí)間和不良反應(yīng)。結(jié)果 治療后,對(duì)照組和治療組總有效率分別為76.0%、88.0%,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組患者皰疹潰瘍消失時(shí)間、流涎消失時(shí)間、退熱時(shí)間、住院時(shí)間均低于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組和治療組不良反應(yīng)發(fā)生率分別為20.0%、8.0%,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 核黃素磷酸鈉聯(lián)合干擾素治療小兒皰疹性咽峽炎具有較好的臨床療效,可縮短皰疹潰瘍消失時(shí)間、流涎消失時(shí)間、退熱時(shí)間、住院時(shí)間,不良反應(yīng)少,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of riboflavin sodium phosphate combined with interferon in the treatment of children herpangina. Methods Patients (100 cases) with herpangina in Maternal and Child Health Care Family Planning Service Center of Shapingba District of Chongqing from October 2012 to April 2015 were randomly divided into control and treatment groups, and each group had 50 cases. All patients were given conventional treatment including physical or drugs cooling, rehydration support and antibiotic therapy. The patients in the control group were iv administered with Recombinant Human Interferon α1b Injection on the basis of conventional treatment, once daily. The amounts of drugs were corresponding with ages of children, such as 6 months—1 year children had 6 μg/time, 1—3 years children had 10 μg/time, but above 3 years children had 20 μg/time. The patients in the treatment group were iv administered with Riboflavin Sodium Phosphate Injection on the basis of the control group, 5—10 mg, once daily. The clinical efficacies of the two groups were observed, and time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization, and adverse reactions were compared between two groups. Results After treatment, the clinical efficacies in the control and treatment groups were 76.0% and 88.0%, respectively, and there were differences between two groups (P< 0.05). Compared with control group, time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization of patients in treatment group were lower, and there were differences between two groups (P< 0.05). The incidence of adverse reactions in the control and treatment groups were 20.0% and 8.0%, respectively, and there were differences between two groups (P< 0.05). Conclusion Riboflavin sodium phosphate combined with interferon has clinical curative effect in the treatment of children herpangina, can reduce time of herpetic ulcer dissipated, salivation dissipated, cooling and hospitalization of patients, and incidence of adverse reactions is few, which has a certain clinical application value.